A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC)
一项 II 期随机、开放标签研究,旨在评估低剂量帕博利珠单抗联合新辅助化疗治疗三阴性乳腺癌 (TNBC) 的疗效。
期刊:Trials
影响因子:2
doi:10.1186/s13063-025-08726-9
Arora, Adhip; Seenu, V; Parshad, Rajinder; Bansal, V K; Dhar, Anita; Mathur, Sandeep; Tanwar, Pranay; Mishra, Piyush; Kataria, Kamal; Suhani; Gogia, Ajay; Kumar, Brijesh; Haresh, K P; Mallick, Supriya; Saini, Surendra Kumar; Mishra, Ashutosh; Bansal, Babul; Sharma, Jyoti; Saikia, Jyoutishman; Rangarajan, Krithika; Dhamija, Ekta; Prasad, Chandra Prakash; Shamin, Shamim Ahmed; Agastm, Sourabh; Kalra, Kaushal; Vishvam, Divvay; Mani, Kalaivani; Kumar, Akash; Bakhshi, Sameer; Batra, Atul